Abstract
The prognosis of patients with recurrent malignant glioma (rMG) is quite poor. According to the NCCN guidelines, bevacizumab is recommended drug for rMG. Anlotinib is a multitarget tyrosine kinase inhibitor that can inhibit tumor angiogenesis and tumor cell growth. We report results from this retrospective study to determine the efficacy and tolerability of Anlotinib plus temozolomide (TMZ) as a first-line treatment for rMG.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.